Pharmacologic combination of atypical antipsychotics and NMDA modulators for the treatment of cognitive impairment, bipolar disorder, cognitive impairment and major depressive disorder

摘要

This disclosure is characterized by the combined use of NMDA modulators and atypical antipsychotics. This disclosure is directed to methods for treating asthma, bipolar disorder and / or cognitive impairment disorder, for example, in a patient in need thereof, comprising administering rapamystel and atypical antipsychotics, for example, .